Roche (VTX:ROG) received a CHF 260 price objective from equities research analysts at UBS Group in a note issued to investors on Tuesday, www.boersen-zeitung.de reports. The brokerage currently has a “neutral” rating on the healthcare company’s stock. UBS Group’s price objective suggests a potential upside of 18.51% from the stock’s current price.
Several other research analysts have also recently weighed in on ROG. DZ Bank set a CHF 270 price target on shares of Roche and gave the stock a “buy” rating in a report on Friday. Barclays set a CHF 295 price target on shares of Roche and gave the stock a “buy” rating in a report on Monday. Sanford C. Bernstein set a CHF 250 price target on shares of Roche and gave the stock a “buy” rating in a report on Friday. JPMorgan Chase & Co. restated a “buy” rating on shares of Roche in a report on Friday. Finally, Deutsche Bank set a CHF 240 price target on shares of Roche and gave the stock a “neutral” rating in a report on Monday. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company’s stock. Roche has an average rating of “Hold” and a consensus price target of CHF 257.20.
Roche (VTX ROG) opened at CHF 219.40 on Tuesday. Roche has a twelve month low of CHF 214.30 and a twelve month high of CHF 273. The firm has a market cap of $190,060.00 and a PE ratio of 21.85.
TRADEMARK VIOLATION WARNING: “Roche (ROG) Given a CHF 260 Price Target at UBS Group” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/06/roche-rog-given-a-chf-260-price-target-at-ubs-group.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.